{"id":626358,"date":"2026-09-16T11:14:15","date_gmt":"2026-09-16T11:14:15","guid":{"rendered":"https:\/\/www.newsbeep.com\/ie\/626358\/"},"modified":"2026-09-16T11:14:15","modified_gmt":"2026-09-16T11:14:15","slug":"peptide-therapy-triumphs-in-phase-i-parkinsons-trials","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/ie\/626358\/","title":{"rendered":"Peptide therapy triumphs in Phase I Parkinson\u2019s trials"},"content":{"rendered":"

Earlier this month, Denmark-based biotechnology company Teitur Trophics announced<\/a> positive Phase I clinical trial results (2025-521357-17-00<\/a>) for its therapeutic peptide, TT-P34. The drug triggers a neuroprotective benefit when exposed to the central nervous system (CNS).<\/p>\n

\u201cOne of the hardest parts of treating Parkinson’s is getting a drug into the brain in a meaningful amount,\u201d co-founder and CEO of Teitur Trophics Simon M\u00f8lgaard explained to BioXconomy. \u201cIn our Phase I trial, we measured how much TT-P34 actually reached the fluid around the brain and spinal cord. The amounts we saw are in the range we believe is needed to have a real effect on the disease.\u201d<\/p>\n

\u201cShowing that the drug reaches the brain and hits its target is an important early sign that we’re on the right track.\u201d<\/p>\n

According to the company, TT-P34 works<\/a> through a dual mechanism, acting on both the lysosomal and mitochondrial dysfunction that contributes to the pathology of Parkinson\u2019s. The peptide originates from the neuro-regulatory SorCS2 transmembrane receptor<\/a>. TT-P34 is designed to reactivate the transcription factor CREB, which is essential for<\/a> neuronal cell health and restores mitochondrial and lysosomal functionality.<\/p>\n

Related:Breakthrough peptide repairs nerves after spinal cord injury in clinical trial<\/a><\/p>\n

\u201cTwo of the best-understood problems in Parkinson’s happen inside brain cells,\u201d M\u00f8lgaard elaborated. \u201cThe first is when mitochondria fail to produce enough energy. The second is when the lysosome, the recycling system, stops clearing away waste effectively. These two together drive disease progression.\u201d<\/p>\n

\u201cMost treatments currently in development tackle only one of these. TT-P34 is designed to improve both at once.\u201d<\/p>\n

As well as demonstrating adequate CNS exposure, the Phase I results also revealed a well-tolerated safety profile and validated a once-weekly dosing schedule.<\/p>\n

The other key readout came from testing the peptide\u2019s effects on lysosomes.<\/p>\n

\u201cIn our trial, most of the Parkinson’s patients who received TT-P34 showed changes in several of these recycling-related proteins in the fluid around the brain, all moving together in a consistent way,\u201d M\u00f8lgaard continued. \u201cThis suggests the drug is reaching the right cells and doing what we designed it to do.\u201d<\/p>\n

Given these early positive results, Teitur Trophics\u2019 plans for TT-P34 are unlikely to slow down anytime soon.<\/p>\n

\u201cOur Phase I results are an early but encouraging sign,\u201d noted M\u00f8lgaard. \u201cOur Phase II trial, planned for 2027, will start to explore whether TT-P34 offers real benefit and can slow the disease.\u201d<\/p>\n

Quotes have been lightly edited for clarity.<\/p>\n

Related:Tiny peptide CAQK triggers damage repair following traumatic brain injury<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Earlier this month, Denmark-based biotechnology company Teitur Trophics announced positive Phase I clinical trial results (2025-521357-17-00) for its…\n","protected":false},"author":2,"featured_media":626359,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[103,61,60],"class_list":["post-626358","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-health","tag-ie","tag-ireland"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/626358","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/comments?post=626358"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/626358\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media\/626359"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media?parent=626358"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/categories?post=626358"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/tags?post=626358"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}